At 11.0% CAGR, the Europe Intradermal injection Market is projected to be worth US$ 2,131.06 million by 2028, says Business Market Insights    

According to the Insight Partners’ research, the Europe intradermal injection market was valued at US$ 1,029.42 million in 2021 and is expected to reach US$ 2,131.06 million by 2028, registering an annual growth rate of 11.0% from 2021 to 2028.Increasing intradermal vaccination and increasing incidences of diseases are the critical factors attributed to the market expansion.                

Rising acceptance of intradermal vaccination is believed to act as major driver for the Europe intradermal injection market as it has several advantages over the conventional method of vaccination. Intradermal vaccination helps in reducing the potential dose of antigens, improves the immune response generated by the vaccine and decrease the anxiety associated with the vaccination. By developing intradermal injection, a large population can be vaccinated with comparatively lesser production of the vaccine while this method is also able to vaccinate the difficult group of population with comorbidities as chances of adverse events is low as compared to conventional vaccination. Recently, several intradermal COVID19 vaccines, hepatitis A vaccine, hepatitis B vaccine, Influenza vaccines, polio vaccine measles vaccine, Rabies vaccine, tetanus vaccine, yellow fever vaccine, diphtheria-tetanus-pertussis vaccine etc. shows improvement in the overall response rate and hence several leading pharmaceutical and biotechnological companies are currently working on the development of intradermal injections of the new as well as commercially available vaccines. Therefore, the efforts made by the leading manufactures is believed to drive the growth rate of this market segment.   

On the contrary, risks, complications, and dosing limitations associated with intradermal injections hurdles the growth of Europe intradermal injection market. 

• Based on method, the Europe intradermal injection market is segmented into normal sized needles, short needle, and without needle. The normal sized needles segment held 38.9% market share in 2021, amassing US$ 400.12 million. It is projected to garner US$ 798.76 million by 2028 to expand at 10.4% CAGR during 2021–2028. The normal sized needles segment is further subsegmented into intradermal microinjection,microneedle arrays,and tattoo devices. The short needle segment is further subsegmented intradermal liquid jet injectors and ballistic intradermal injectors.
• Based on application, the Europe intradermal injection market is segmented into tuberculin skin test, allergy test, local aesthetics, and others. The tuberculin skin test segment held 29.0% market share in 2021, amassing US$ 298.12 million. It is projected to garner US$ 607.33 million by 2028 to expand at 10.7% CAGR during 2021–2028.
• Based on end user, the Europe intradermal injection market is segmented into hospitals, diagnostic laboratories, academics and research institutes, and others. The hospitals segment held 39.8% market share in 2021, amassing US$ 409.52 million. It is projected to garner US$ 855.35 million by 2028 to expand at 11.1% CAGR during 2021–2028.
• Based on country, the Europe intradermal injection market has been categorized into U.K., Germany, France, Italy, Spain, and rest of Europe.  Our regional analysis states that Germany captured 25.5% market share in 2021. It was assessed at US$ 262.48 million in 2021 and is likely to hit US$ 549.98 million by 2028, exhibiting a CAGR of 11.1% during the forecast period.  

Key players profiles in the Europe intradermal injection market report are BD; West Pharmaceutical Services, Inc; Terumo Corporation; Nanopass; PharmaJet; Idevax; Eunsung Global; Crossject; Cardinal Health Inc; and Hindustan Syringes and Medical Devices Ltd among others.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com